抗血小板药物胃肠道损伤及其预防策略的研究进展

Research advances on anti-platelet drug-induced gastrointestinal injury and its prevention

抗血小板治疗已成为防治心脑血管疾病的基石,随着我国心脑血管疾病患病率的不断攀升,服用抗血小板药物的患者越来越多。胃肠道损伤是抗血小板药物最常见的不良反应,如不采取预防措施,其消化道出血(GIB)的风险甚至可覆盖其预防心脑血管疾病的获益,因此备受关注。近年来,随着相关循证医学研究的不断深入,抗血小板药物相关胃肠道损伤的研究已有诸多进展,本文就临床常用抗血小板药物对胃肠道损伤的流行病学特征、机制及预防策略的最新研究进展做一综述。

Anti-platelet therapy has become the cornerstone of cardiovascular and cerebrovascular disease prevention and treatment.As the prevalence of cardiovascular and cerebrovascular diseases continues to rise in China,there are a growing number of patients taking antiplatelet drugs.Gastrointestinal tract injury is the most common adverse reaction of anti-platelet drugs.If no preventive measures are taken,the risk of gastrointestinal bleeding(GIB)caused by these drugs can outweigh their benefits of cardiovascular and cerebrovascular disease prevention.Therefore,the issue has become a major concern.In recent years,with the development of evidence-based medicine,considerable research advances have been made on anti-platelet drug-related gastrointestinal injury.In this article,the latest research progress on the epidemiological characteristics,mechanisms and prevention strategies about anti-platelet drug-induced gastrointestinal injury is reviewed.